Pricing Log in Create free account
Friday 6 November 2026 Export DNTH’s income statement to Excel — free account

Dianthus Therapeutics, Inc.

DNTH Healthcare Biotechnology

Dianthus Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 67.3% from fiscal 2024.

Revenue
+205.6%
EPS
+16.1%
Free cash flow
−65.9%

Quarter to September 2026, against a year earlier

86.43 3.42 +4.12%
Market cap
$4.6B
P/E
0.0×
Fwd P/E
−21.5×
Dividend yield
—
F-score
2/9
Altman Z
24.31
Beneish M
−4.75
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Dianthus Therapeutics, Inc. (DNTH) P/E ratio

Alert me on P/E ratio

Dianthus Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
13 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
LEGN Legend Biotech Corporation Sponsored ADR compare n/m
DFTX Definium Therapeutics, Inc. compare n/m
ERAS Erasca, Inc. compare n/m
TVTX Travere Therapeutics, Inc. compare n/m
DNTH Dianthus Therapeutics, Inc. n/m
MANE Veradermics Incorporated compare n/m
CRSP CRISPR Therapeutics AG compare n/m
COGT Cogent Biosciences, Inc. compare n/m
EWTX Edgewise Therapeutics, Inc. compare 4.9×
Biotechnology industry median 10.6×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on DNTH